F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comStrides Pharma Science Ltd is one of India’s most prominent pharmaceutical companies, known for its strong presence in regulated markets, diversified product portfolio, and consistent R&D focus. With its global footprint and strong execution capabilities, Strides Pharma continues to attract long-term investors. This article explores the company’s share price targets from 2025 to 2030, along with insights into its fundamentals and future growth potential.
Below are the latest stock-related details:
| Detail | Value |
|---|---|
| Open | ₹960.00 |
| Previous Close | ₹966.15 |
| Volume | 2,06,446 |
| Value (Lacs) | ₹2,008.10 |
| VWAP | ₹959.25 |
| Beta | 1.29 |
| Market Cap | ₹8,965 Cr |
| Day High | ₹972.70 |
| Day Low | ₹941.90 |
| UC Limit | ₹1,159.35 |
| LC Limit | ₹772.95 |
| 52-Week High | ₹1,655.00 |
| 52-Week Low | ₹513.05 |
| Face Value | ₹10 |
| All-Time High | ₹1,675.00 |
| All-Time Low | ₹47.10 |
Strides Pharma Science Ltd is a well-established pharmaceutical manufacturer that produces a wide range of generic medicines across regulated and emerging markets. With highly advanced manufacturing facilities approved by global authorities such as USFDA and EMA, the company exports products to over 100 countries.
Its core business areas include:
Regulated Markets (US, Europe, Australia)
Institutional Business
R&D-driven new product development
OTC and branded generics
Global distribution and contract manufacturing
The company is known for its high-margin products, expansion into specialty pharmaceuticals, and consistent innovation in formulations.
Strong global presence across regulated markets
High-quality manufacturing capabilities
Robust research and development investments
Steady product approvals in the US and Europe
Focus on diversified therapeutic segments
| Investor Category | Holding (%) |
|---|---|
| Retail & Others | 30.64% |
| Foreign Institutions | 28.51% |
| Promoters | 27.86% |
| Mutual Funds | 8.48% |
| Other Domestic Institutions | 4.51% |
The balanced shareholding pattern indicates strong institutional interest and steady promoter confidence.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2025 | 1,050 | 1,150 |
| 2026 | 1,180 | 1,290 |
| 2027 | 1,320 | 1,450 |
| 2028 | 1,470 | 1,620 |
| 2029 | 1,640 | 1,780 |
| 2030 | 1,820 | 2,000 |
These projections consider the company’s financial performance, regulatory approvals, product pipeline, and global market expansion.
In 2025, Strides Pharma is expected to sustain growth through strong sales in the US and continued demand for generic medicines.
Key drivers:
Steady USFDA approvals
Growth in over-the-counter and branded generics
Successful launches in regulated markets
By 2026, the company may experience higher profitability from operational efficiency and cost optimization.
Why growth is expected:
Strong order book in institutional business
New product launches in chronic therapeutic areas
Increasing demand in global markets
Strides Pharma may see enhanced returns due to its expanding specialty and high-margin pharmaceutical segments.
Growth support:
Better margins from niche formulations
Expanding international partnerships
Improved manufacturing utilization
By 2028, ongoing capacity expansion and technological upgrades may boost performance further.
Positive factors:
Strong distribution network
Higher export volumes
Increasing presence in emerging markets
With continued regulatory success and global demand for generic medicines, Strides Pharma may achieve steady upward momentum.
Contributors to growth:
Strategic global acquisitions
Entry into new therapeutic categories
Improving revenue visibility
Strides Pharma may evolve into a leading global pharmaceutical exporter by 2030.
Long-term drivers:
Strong leadership and long-term strategy
Consistent regulatory compliance
Growth in specialty generics and chronic care products
Strides Pharma is a strong long-term pick for investors seeking exposure to the pharmaceutical and healthcare sector. With its global presence, steady approvals, and strong R&D strategy, the company offers the potential for consistent returns.
Strong international business
Diversified product pipeline
Healthy promoter and institutional participation
Focus on profitability and global expansion
Regulatory challenges
Pricing pressure in US and European markets
Currency fluctuations affecting export revenues
Investors should consider company fundamentals and personal risk tolerance before investing.
Strides Pharma Science Ltd continues to strengthen its position in the global pharmaceutical industry through innovation, quality manufacturing, and a strong global footprint. With a solid track record and promising growth prospects, the company is expected to deliver significant value in the coming years.
Based on current performance and market outlook, Strides Pharma could potentially reach ₹2,000 by 2030. For investors seeking long-term growth in the pharma sector, Strides Pharma can be a valuable addition to a diversified portfolio.
Register & Login